News
CRL
250.35
-3.68%
-9.57
Jim Cramer Says This Stock Is Undervalued: 'I Think That It's Coming Back'
Benzinga · 2d ago
Charles River acquires SAMDI Tech for $50M in cash
Seeking Alpha · 5d ago
Charles River Laboratories International Closes Purchase of SAMDI Tech
Charles River Laboratories International Closes Purchase of SAMDI Tech
MT Newswires · 5d ago
iVexSol closes $23.8M series A-3 financing by Bristol Myers Squibb, Charles River, Asahi Kasei
Seeking Alpha · 01/26 16:40
Charles River Laboratories, AbbVie, Star Bulk Carriers And This Big Bank Are CNBC's 'Final Trades'
Benzinga · 01/23 13:40
This Favorable Sign Appears On Charles River's Chart
Benzinga · 01/19 14:48
BRIEF-Charles River And Rznomics Announce RNA-based Anticancer Gene Therapy Manufacturing Alliance
Reuters · 01/18 13:10
Charles River Laboratories Partners With South Korea's Rznomics to Manufacture RNA-Based Anticancer Gene Therapy
Charles River Laboratories Partners With South Korea's Rznomics to Manufacture RNA-Based Anticancer Gene Therapy
MT Newswires · 01/18 09:10
What Does Charles River's Debt Look Like?
Benzinga · 01/12 18:06
BRIEF-Charles River Establishes eXpDNA Plasmid Manufacturing Platform To Expedite DNA Programs
Reuters · 01/12 13:49
Charles River cut to Hold at Jefferies on biotech funding and supply concerns
Seeking Alpha · 01/12 13:48
Jefferies Downgrades Charles River to Hold
Benzinga · 01/12 12:26
Jefferies Downgrades Charles River Laboratories International to Hold From Buy, Adjusts Price Target to $233 From $250
Jefferies Downgrades Charles River Laboratories International to Hold From Buy, Adjusts Price Target to $233 From $250
MT Newswires · 01/12 09:42
Baird Maintains Outperform on Charles River, Raises Price Target to $285
Benzinga · 01/11 14:42
Baird Adjusts Price Target on Charles River Laboratories International to $285 From $275, Maintains Outperform Rating
Baird Adjusts Price Target on Charles River Laboratories International to $285 From $275, Maintains Outperform Rating
MT Newswires · 01/11 11:01
Charles River Laboratories Sells Avian Vaccine Services Business to Arlington Capital Partners
Charles River Laboratories Sells Avian Vaccine Services Business to Arlington Capital Partners
MT Newswires · 01/05 10:54
Tracking John Rogers' Ariel Investments Portfolio - Q3 2022 Update
Seekingalpha · 12/28/2022 03:44
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2022 Update
Seekingalpha · 12/26/2022 07:27
You may be overlooking high-quality stocks in this part of the market
Marketwatch.com · 12/12/2022 18:04
BRIEF-Charles River Laboratories International Inc Says Effective December 5, 2022, Board Of Co Increased Size Of Board From Ten To Eleven - Filing
Reuters · 12/06/2022 22:35
More
Webull provides a variety of real-time CRL stock news. You can receive the latest news about Charles Riv Labs Intl Inc through multiple platforms. This information may help you make smarter investment decisions.
About CRL
Charles River Laboratories International, Inc. is a full service, non-clinical contract research company. The Company provides research models required in research and development of new drugs, devices, and therapies. The Company's segments include Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment includes the research models, research model services, and research and GMP-compliant cells businesses. The DSA segment includes services required to take a drug through the early development process, including discovery services, which are non-regulated services to assist clients with the identification, screening, and selection of a lead compound for drug development, and regulated and non-regulated (Good Laboratory Practice (GLP) and non-GLP) safety assessment services. The Manufacturing segment includes Microbial Solutions and Biologics Solutions (Biologics).